CAR T-cell therapy targeting CD19 antigen has achieved a remarkable therapeutic efficacy in treating relapse or refractory B-cell malignancies, culminating in the regulatory approval of two CAR T-cell products for patients with certain leukemia and lymphoma (1, 2); in addition, CAR T cells targeting other antigens, such as BCMA and CD22, have also exhibited a promising therapeutic potential in treating some type of intractable leukemia and multiple myeloma (5–7). Here, CD22 is linked to leukemia.